Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BB2001
- Development stage
- Preclinical
- Lead developer
- Bluedot Bio
- Modality
- Peptides
01
Overview
BB2001 is a discovery-stage cyclic peptide decoy developed by Bluedot Bio that targets the MYC (c-Myc) transcription factor. MYC is a master regulator of cell growth and metabolism that is frequently overexpressed in many cancers but has been difficult to target with traditional small molecules. BB2001 is designed to function as a molecular decoy, mimicking the DNA sequences or protein interfaces that MYC binds to, thereby preventing MYC from activating its downstream oncogenic gene expression program. This approach aims to provide a therapeutic option for a broad range of MYC-driven malignancies.
- Other names
- BB2001 cyclic MYC decoyBB-2001 cyclic MYC decoyBB 2001 cyclic MYC decoy
02
Targets
MYC (MYC proto-oncogene protein)
Beyond the preview
Go deeper on BB2001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BB2001.